Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ralaniten acetate - ESSA Pharma

Next Previous
X
Search
Drug Profile

Ralaniten acetate - ESSA Pharma

Alternative Names: EPI 506

Latest Information Update: 31 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ESSA Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 01 Dec 2017 ESSA Pharmaceuticals terminates a phase I/II trial in Prostate cancer (Hormone refractory, Second-line therapy or greater) in United Kingdom, USA, Canada due to excessive high pill burden at the end of phase I (PO) (NCT02606123)
  • 11 Sep 2017 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Second-line therapy or greater) in Canada and USA (PO)
  • 09 Sep 2017 Updated efficacy and safety data from a phase I/II trial in Prostate cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top